SMi Group present the 2017 8th annual event on Biosimilars & Biobetters, taking place on 27-28 Sept in London, UK.
As the patents for several innovator biologics expire, biopharmaceutical companies are taking the opportunity to develop more affordable forms creating a rapidly booming biosimilars market. However, as the field of biosimilars evolves, challenges in immunogenicity studies, securing market share, exclusivity and regulations still persist.
Join us this autumn to arm yourself with the key requirements and tools for successful market entry through strategic direction on commercialisation; insight into potential therapeutic areas; and critical updates on interchangeability guidelines and patient litigation.
FEATURED SPEAKERS:
Bernd Liedert, Snr Clinical Program Leader Biosimilars, Boehringer Ingelheim
Ho-Ung Kim, Division Head Strategy & Operations, Celltrion Healthcare
Sarah Rickwood, VP, Head of European Thought Leadership, QuintilesIMS
Matthew Turner, Global Medical Dir, Biosimilars, Merck Group
Steiner Madsen, Medical Dir, Norwegian Medicines Agency
Thomas Sachnik, Snr Manager Strategic Associate to the President & CEO Generics Europe, Teva
Harish Pai, Principal Scientific Manager, Biocon
Ildiko Aradi, Head Clinical Development of Biologics, Gedeon Richter
Glenn Kazo, President & COO, Prolong Pharmaceuticals
INDUSTRY LEVERAGE:
• Increase speed of entry and compliance through informed guidance on interchangeability, patient litigation and IP laws
• Develop strategies for market access and expansion by identifying future projections
• Evolve clinical developments through insight into orphan drugs, in-vitro functional assays and data extrapolation
• Create a competitive edge through an understanding on switching studies
• Hear case studies on required testing such as immunogenicity and bio-similarity tests
• Discuss solutions in exclusivity and HCP acceptance
• Unique coverage of biobetters from experts in the field
Price
Conference + 2 Workshops: GBP 2697
Conference +1 Workshop: GBP 2098
Conference Only: GBP 1499
As the patents for several innovator biologics expire, biopharmaceutical companies are taking the opportunity to develop more affordable forms creating a rapidly booming biosimilars market. However, as the field of biosimilars evolves, challenges in immunogenicity studies, securing market share, exclusivity and regulations still persist.
Join us this autumn to arm yourself with the key requirements and tools for successful market entry through strategic direction on commercialisation; insight into potential therapeutic areas; and critical updates on interchangeability guidelines and patient litigation.
FEATURED SPEAKERS:
Bernd Liedert, Snr Clinical Program Leader Biosimilars, Boehringer Ingelheim
Ho-Ung Kim, Division Head Strategy & Operations, Celltrion Healthcare
Sarah Rickwood, VP, Head of European Thought Leadership, QuintilesIMS
Matthew Turner, Global Medical Dir, Biosimilars, Merck Group
Steiner Madsen, Medical Dir, Norwegian Medicines Agency
Thomas Sachnik, Snr Manager Strategic Associate to the President & CEO Generics Europe, Teva
Harish Pai, Principal Scientific Manager, Biocon
Ildiko Aradi, Head Clinical Development of Biologics, Gedeon Richter
Glenn Kazo, President & COO, Prolong Pharmaceuticals
INDUSTRY LEVERAGE:
• Increase speed of entry and compliance through informed guidance on interchangeability, patient litigation and IP laws
• Develop strategies for market access and expansion by identifying future projections
• Evolve clinical developments through insight into orphan drugs, in-vitro functional assays and data extrapolation
• Create a competitive edge through an understanding on switching studies
• Hear case studies on required testing such as immunogenicity and bio-similarity tests
• Discuss solutions in exclusivity and HCP acceptance
• Unique coverage of biobetters from experts in the field
Price
Conference + 2 Workshops: GBP 2697
Conference +1 Workshop: GBP 2098
Conference Only: GBP 1499
